Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes
Logan Roof, Jessica L Geiger Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USACorrespondence: Jessica L Geiger, Cleveland Clinic Taussig Cancer Institute, 10201 Carnegie Avenue, CA Building CA 60, Cleveland, OH, 44106, USA, Tel +1216 444-0...
Main Authors: | Roof L, Geiger JL |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-04-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-utility-of-cabozantinib-in-the-treatment-of-locally-advanced--peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022-06-01) -
Kinase inhibitors in thyroid cancers
by: Vineeth Sukrithan, et al.
Published: (2024-02-01) -
Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
by: Michael H. Storandt, et al.
Published: (2022-10-01) -
Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
by: Linnea Højer Wang, et al.
Published: (2023-01-01) -
Cabozantinib: A narrative drug review
by: Vivek K Srigadha, et al.
Published: (2023-01-01)